Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

2022415 citationsJournal Articlebronze Open Access

Authors

Michael B. Atkins · Georgetown University

Sandra J. Lee · Harvard University

Bartosz Chmielowski · Georgetown University

Ahmad A. Tarhini · Moffitt Cancer Center

Gary I. Cohen · Greater Baltimore Medical Center

Thach‐Giao Truong · Kaiser Permanente Vallejo Medical Center

Helen Moon

Abstract

Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.

Topics & Keywords

Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 2, pp. 186-197

DOI: 10.1200/jco.22.01763

Field-Weighted Citation Impact: 34.83